Regeneron Pharmaceuticals (REGN) Earnings Date & Reports

Key Takeaways

• Regeneron Pharmaceuticals (REGN) is expected to report third-quarter 2026 results in late October, following a second quarter in which revenue rose 17% year over year to $4.29 billion.
• Investors will focus on Dupixent's global net sales, which reached a record $6.0 billion in Q2 2026, up 38% year over year on a constant-currency basis.
• EYLEA HD momentum remains a central theme after U.S. net sales climbed 52% to $596 million, while legacy EYLEA sales fell 45% amid biosimilar competition and patient conversion.
• Management has signaled that Sanofi collaboration revenue should "step up" in Q3 after full repayment of the roughly $3.1 billion development balance.
• Regulatory catalysts, including a U.S. Food and Drug Administration (FDA) decision on cemdisiran for generalized myasthenia gravis (gMG) targeted for November 2026, are key swing factors.

Earnings Context and Why It Matters

Regeneron's quarterly report is a closely watched event in the biotech space because the company's results hinge on a small group of blockbuster franchises. Dupixent, marketed with Sanofi, and the EYLEA ophthalmology franchise have historically driven the bulk of value, making each quarter's sales trajectory a critical signal for the broader business. The Q3 report will test whether the transition from legacy EYLEA to the higher-dose EYLEA HD can offset ongoing biosimilar pressure, and whether Dupixent's multi-indication expansion can sustain its rapid growth. With roughly 50 clinical programs in development and several near-term regulatory milestones, the report also offers a read on Regeneron's ability to convert pipeline momentum into long-term revenue diversification.

Earnings Expectations

Regeneron follows a standard calendar-year fiscal calendar, so the upcoming third quarter covers July through September 2026. Heading into the release, the market's attention is less on a single headline figure and more on the durability of the company's top-line growth engines. In Q2 2026, total revenues reached $4.29 billion and non-GAAP diluted earnings per share (EPS) came in at $14.29, up 11% year over year and ahead of consensus, helped by a reduced share count and higher collaboration revenue. Non-GAAP figures exclude certain one-time items to show underlying performance.

Management's directional guidance is a key input for the quarter. The company has said Sanofi collaboration revenue should step up beginning in Q3 now that the prior development balance is fully repaid. It also expects legacy EYLEA U.S. demand to decline sequentially in the low- to mid-teens through the second half, while EYLEA HD demand should grow sequentially in the low- to mid-teens. Dupixent growth is expected to remain strong but moderate versus the first half as recent launches annualize and prior-year comparisons become tougher. Investors will also watch research and development (R&D) spending, gross margin trends, and any updates to full-year 2026 guidance.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For those tracking earnings-driven movers like Regeneron, it offers a structured way to surface potential setups ahead of key events.

Market Reaction and Investor Sentiment

Sentiment entering the quarter reflects a balancing act between strong commercial execution and lingering competitive risks. Regeneron's shares have trailed parts of the biotech sector in 2026, reflecting concerns about the legacy EYLEA franchise and delayed approval of the EYLEA HD prefilled syringe. Offsetting those concerns, the company has now posted consecutive quarters of double-digit growth in both revenue and non-GAAP EPS. Heading into Q3, the key risk factors are biosimilar launches in ophthalmology, a temporary production interruption that pressured gross margins, and regulatory timing uncertainty. A beat-and-raise on the back of Dupixent and EYLEA HD could reinforce the growth narrative, while any sign of EYLEA HD deceleration or disappointing collaboration revenue could weigh on the stock.

Forward Outlook and Key Factors to Monitor

Beyond the headline numbers, investors should watch several catalysts that could shape Regeneron's trajectory. The FDA is expected to decide on cemdisiran, a C5 RNAi therapy for gMG, with a target action date in November 2026 following priority review. Approval would add a new treatment option in a market Regeneron already understands well.

The EYLEA HD prefilled syringe remains an important product enhancement, with management aiming for approval before the end of 2026. Resolving the manufacturing and regulatory issues tied to the prior complete response letter could support further EYLEA HD adoption and dosing flexibility.

Investors should also monitor the obesity portfolio, which management has flagged as advancing toward Phase 3 development, as well as garetosmab for fibrodysplasia ossificans progressiva (FOP), a rare bone disorder. Dupixent's expansion into younger age groups and international markets, along with Libtayo's growing share in non-small cell lung cancer, round out the key growth levers.

Finally, cost and margin trends matter. R&D spending is rising as the pipeline advances, and gross margin faced temporary pressure from unabsorbed manufacturing costs. How these expenses evolve will influence the pace of earnings growth even as revenue accelerates.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations